First-Line [ 177 Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Journal of Nuclear Medicine · 2025-11 · 66 (11) · 1684-1687
DOI: 10.2967/jnumed.125.270704 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 25.09.2025. Verfasst von Vinay K Giri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Lutetium, Prostatic Neoplasms, Prostate-Specific Antigen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
The treatment of metastatic prostate cancer relies on the use of androgen deprivation therapy, which is associated with many side effects, including adverse cardiovascular outcomes. 177Lu-vipivotide tetraxetan ([177Lu]Lu-PSMA-617) is used in the treatment of prostate-specific membrane antigen-expressing metastatic castration-resistant prostate adenocarcinoma. We present the case of a patient with prostate cancer with numerous metastatic lesions who declined androgen deprivation therapy, chemotherapy, and local therapy to the prostate gland and instead received first-line systemic [177Lu]Lu-PSMA-617. He exhibited a significant response in both the primary cancer and its metastatic foci after 2 doses of the treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Harvard Medical School, Boston, Massachusetts.
- Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
- Department of Radiology, Division of Nuclear Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
- Harvard Medical School, Boston, Massachusetts; mgarnick@bidmc.harvard.edu.
Zitieren
APA
Giri, V. K., Kolodny, G. M., & Garnick, M. B. (2025). First-Line [ 177 Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer. Journal of Nuclear Medicine, 66(11), 1684-1687. https://doi.org/10.2967/jnumed.125.270704
Vancouver
Giri VK, Kolodny GM, Garnick MB. First-Line [ 177 Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer. Journal of Nuclear Medicine. 2025;66(11):1684-1687. doi:10.2967/jnumed.125.270704
BibTeX
@article{Giri2025,
author = {Giri, Vinay K and Kolodny, Gerald M and Garnick, Marc B},
title = {First-Line [ 177 Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer},
journal = {Journal of Nuclear Medicine},
year = {2025},
volume = {66},
number = {11},
pages = {1684--1687},
doi = {10.2967/jnumed.125.270704}
}
EUVIMED